CONCLUSIONS: Dual PD-L1/PD-L2 blockade synergizes with STING pathway activation to promote immune and vascular remodeling, resulting in superior antitumor efficacy in preclinical tumor models. Here, PDCD1LG2 is linked to neoplasm.